PROFESSIONAL POST

Attending physician, Department of nephrology

Assistant professor, Chang Gung university

Education

MEDICAL SCHOOL, TAIPEI MEDICAL UNIVERSITY

RESEARCH INTEREST

Lupus nephritis

Toxicolgy

AWARD

Research award, Taiwan society of nephrology, 2005

Professional ACTIVITIES

Director, Division of artificial kidney

MAJOR BIBLIOGRAPHY (limited 10 papers)

1.Weng CH, Hu CC, Yu CC, Lin JL, Yang CW, Hung CC, Hsu CW, Yen TH. Immunoglobulin G levels can 

predict non-diabetic renal disease in patients with type 2 diabetes mellitus. J Diabetes. 2012 Mar;4(1):37-40.

2.Weng CH, Hsu CW, Yu CC, Yen TH, Yang CW, Hung C. Peritoneal Dialysis and Hemodialysis in Systemic Lupus Erythematosus Patients: Comparison of Clinical Outcomes. Kidney Blood Press Res 2009 Dec;32(6):451-456.

3.Lin JL, Lin-Tan DT, Yu CC, Li YJ, Huang YY, Li KL: Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int 2006;69(11):2049-2056.

4.Yu CC, Lin JL, Lin-Tan DT: Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol 2004 Apr;15(4):1016-1022.

5.Lin JL, Lin-Tan DT, Hsu KH, Yu CC: Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003; 348(4):277-286.

6.Lin JL, Yu CC, Lin-Tan DT, Ho HH: Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int 2001; 60(1):266-271.

7.Yu CC, Yang CW, Wu MS, Ko YC, Huang CT, Hong JJ, Huang CC: Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med 2001; 138(1):69-77. (NSC89-2320-B-182A-005)

8.Lin JL, Ho HH, Yu CC: Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med 1999; 130(1):7-13.

9.Yang CW, Yu CC, Ko YC, Huang CC: Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice. Clin Exp Immunol 1998; 113(2):258-264.